Eight Themes That Will Shape Biopharma In Transformational 2021
A year after COVID-19 first turned the world upside down, executives across the biopharma industry consider what 2021 holds in store. The impact of the pandemic will have profound and long-lasting implications for a sector that has been at the heart of responding to the global health challenge.
You may also be interested in...
Global Herd Immunity Against COVID-19 Unlikely, Says Ebola Vaccine Developer
As coronavirus variants keep emerging, global herd immunity is unlikely, says Steven Jones, one of the developers of the first Ebola vaccine. In a wide-ranging discussion with McKinsey, he and other experts weighed in on ways to live with COVID-19, which is expected to soon become endemic.
2021 Opportunities For Healthtech Investment: A Legal Firm’s View
For life sciences investors, the past year has been the busiest period in recent memory, say Goodwin partners Sophie McGrath and David Mardle. But what are the industry's drivers and key investor trends in 2021?
Top-Selling Drugs 2022: Strong Growth In Blockbuster Ranks
COVID-19 products contributed almost a third to the global revenues from the top 20 best-selling drugs in 2022. However, strong growth was also seen for drugs across categories from immunology and cancer to HIV and cardiometabolic.